199 related articles for article (PubMed ID: 21992031)
1. Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary?
Obach RS; Nedderman AN; Smith DA
Xenobiotica; 2012 Jan; 42(1):46-56. PubMed ID: 21992031
[TBL] [Abstract][Full Text] [Related]
2. Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how?
Penner N; Xu L; Prakash C
Chem Res Toxicol; 2012 Mar; 25(3):513-31. PubMed ID: 22309195
[TBL] [Abstract][Full Text] [Related]
3. Human radiolabeled mass balance studies: objectives, utilities and limitations.
Penner N; Klunk LJ; Prakash C
Biopharm Drug Dispos; 2009 May; 30(4):185-203. PubMed ID: 19544285
[TBL] [Abstract][Full Text] [Related]
4. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
Walker D; Brady J; Dalvie D; Davis J; Dowty M; Duncan JN; Nedderman A; Obach RS; Wright P
Chem Res Toxicol; 2009 Oct; 22(10):1653-62. PubMed ID: 19715349
[TBL] [Abstract][Full Text] [Related]
5. Metabolites in safety testing.
Robison TW; Jacobs A
Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
[TBL] [Abstract][Full Text] [Related]
6. The early estimation of circulating drug metabolites in humans.
Luffer-Atlas D
Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):985-97. PubMed ID: 22681256
[TBL] [Abstract][Full Text] [Related]
7. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment.
Smith DA; Obach RS
Chem Res Toxicol; 2009 Feb; 22(2):267-79. PubMed ID: 19166333
[TBL] [Abstract][Full Text] [Related]
8. The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?
Nassar AE; Talaat RE; Kamel AM
Curr Opin Drug Discov Devel; 2006 Jan; 9(1):61-74. PubMed ID: 16445118
[TBL] [Abstract][Full Text] [Related]
9. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
Vishwanathan K; Babalola K; Wang J; Espina R; Yu L; Adedoyin A; Talaat R; Mutlib A; Scatina J
Chem Res Toxicol; 2009 Feb; 22(2):311-22. PubMed ID: 19067650
[TBL] [Abstract][Full Text] [Related]
10. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
Srinivas NR
Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
[TBL] [Abstract][Full Text] [Related]
11. Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies.
Isin EM; Elmore CS; Nilsson GN; Thompson RA; Weidolf L
Chem Res Toxicol; 2012 Mar; 25(3):532-42. PubMed ID: 22372867
[TBL] [Abstract][Full Text] [Related]
12. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.
Leclercq L; Cuyckens F; Mannens GS; de Vries R; Timmerman P; Evans DC
Chem Res Toxicol; 2009 Feb; 22(2):280-93. PubMed ID: 19183054
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy.
Obach RS
Pharmacol Rev; 2013 Apr; 65(2):578-640. PubMed ID: 23406671
[TBL] [Abstract][Full Text] [Related]
14. Addressing metabolite safety during first-in-man studies using ¹⁴C-labeled drug and accelerator mass spectrometry.
Lappin G; Seymour M
Bioanalysis; 2010 Jul; 2(7):1315-24. PubMed ID: 21083242
[TBL] [Abstract][Full Text] [Related]
15. Metabolites in safety testing: metabolite identification strategies in discovery and development.
Nedderman AN
Biopharm Drug Dispos; 2009 May; 30(4):153-62. PubMed ID: 19544286
[TBL] [Abstract][Full Text] [Related]
16. Predicting circulating human metabolites: how good are we?
Anderson S; Luffer-Atlas D; Knadler MP
Chem Res Toxicol; 2009 Feb; 22(2):243-56. PubMed ID: 19138063
[TBL] [Abstract][Full Text] [Related]
17. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites.
Prueksaritanont T; Lin JH; Baillie TA
Toxicol Appl Pharmacol; 2006 Dec; 217(2):143-52. PubMed ID: 17055014
[TBL] [Abstract][Full Text] [Related]
18. Radiolabeled mass-balance excretion and metabolism studies in laboratory animals: a commentary on why they are still necessary.
White RE; Evans DC; Hop CE; Moore DJ; Prakash C; Surapaneni S; Tse FL
Xenobiotica; 2013 Feb; 43(2):219-25; discussion 226-7. PubMed ID: 22803803
[TBL] [Abstract][Full Text] [Related]
19. Assessment of exposure of metabolites in preclinical species and humans at steady state from the single-dose radiolabeled absorption, distribution, metabolism, and excretion studies: a case study.
Prakash C; Li Z; Orlandi C; Klunk L
Drug Metab Dispos; 2012 Jul; 40(7):1308-20. PubMed ID: 22474055
[TBL] [Abstract][Full Text] [Related]
20. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.
Dalvie D; Obach RS; Kang P; Prakash C; Loi CM; Hurst S; Nedderman A; Goulet L; Smith E; Bu HZ; Smith DA
Chem Res Toxicol; 2009 Feb; 22(2):357-68. PubMed ID: 19146377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]